Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: Uncovering novel targets to treat depression

Journal of Neuroscience

Volumn 33, Issue 25, 2013, Pages 10534-10543

  Horton, Rebecca E ^a   Apple, Deana M ^a   Owens, W Anthony ^a   Baganz, Nicole L ^a,c   Cano, Sonia ^a   Mitchell, Nathan C ^a   Vitela, Melissa ^a   Gould, Georgianna G ^a   Koek, Wouter ^a,b   Daws, Lynette C ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DECYNIUM 22; FLUVOXAMINE; OCTAMER TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPAL CA3 REGION; IMMOBILIZATION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROPHYSIOLOGICAL PHENOMENA; FLUVOXAMINE; HINDLIMB SUSPENSION; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROINJECTIONS; NEUROTRANSMITTER TRANSPORT PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; QUINOLINES; SEROTONIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84879161518     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5687-11.2013     Document Type: Article

References (73)

1. Amphoux A, Vialou V, Drescher E, Bruss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941-952. CrossRef Medline
2. Amphoux A, Millan MJ, Cordi A, Bönisch H, Vialou V, Mannoury la Cour C, Dupuis DS, Giros B, Gautron S (2010) Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human alpha 1- and alpha 2-adrenoceptor subtypes. Eur J Pharmacol 634:1-9. CrossRef Medline
3. Ansah TA, Ramamoorthy S, Montañez S, Daws LC, Blakely RD (2003) Calcium-dependent inhibition of synaptosomal serotonin transport by the alpha 2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]- 6-quinoxalinamine (UK14304). J Pharmacol Exp Ther 305:956-965. CrossRef Medline
4. Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, Louis F, Vialou V, Martres MP, Chevarin C, Hamon M, Giros B, Gautron S (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926-939. CrossRef Medline
5. Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic-Zivanovic N, Jeske NA, Koek W, Toney GM, Daws LC (2008) Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 105: 18976-18981. CrossRef Medline
6. Baganz N, Horton R, Martin K, Holmes A, Daws LC (2010) Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 30:15185-15195. CrossRef Medline
7. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501. Medline
8. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressantinduced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22:6766-6772. Medline
9. Benmansour S, Weaver RS, Barton AK, Adeniji OS, Frazer A (2012) Comparison of the effects of estradiol and progesterone on serotonergic function. Biol Psychiatry 71:633-641. CrossRef Medline
10. Bertler A, Falck B, Owman C (1964) Studies on 5-hydroxytryptamine stores in pineal gland of rat. Acta Physiol Scand [Suppl 239]:1-18. Medline
11. Blackburn TP, Kemp JD, Martin DA, Cox B (1984) Evidence that 5-HT agonist-induced rotational behaviour in the rat is mediated via 5-HT1 receptors. Psychopharmacology 83:163-165. CrossRef Medline
12. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ (1998) Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 44:169-178. CrossRef Medline
13. Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29:417-426. Medline
14. Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. implications for the etiology and therapy of depression. Arch Gen Psychiatry 38:1160-1180. CrossRef Medline
15. Chen Z, Skolnick P (2007) Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 16:1365-1377. CrossRef Medline
16. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625. CrossRef Medline
17. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106: 8043-8048. CrossRef Medline
18. Dahlin A, Xia L, Kong W, Hevner R, Wang J (2007) Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146:1193-1211. CrossRef Medline
19. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM (2003) Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 140:1128-1136. CrossRef Medline
20. Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121:89-99. CrossRef Medline
21. Daws LC, Toney GM (2007) High-speed chronoamperometry to study kinetics and mechanisms for serotonin clearance in vivo. In: Electrochemical methods for neuroscience (Michael AC, Borland LM, eds). Boca Raton, FL: Taylor and Francis.
22. Daws LC, Toney GM, Gerhardt GA, Frazer A (1998) In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther 286:967-976. Medline
23. Daws LC, Gould GG, Teicher SD, Gerhardt GA, Frazer A (2000) 5-HT(1B) receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J Neurochem 75:2113-2122. Medline
24. Daws LC, Moñtanez S, Owens WA, Gould GG, Frazer A, Toney GM, Gerhardt GA (2005) Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. J Neurosci Methods 143:49-62. CrossRef Medline
25. Daws LC, Koek W, Mitchell NC (2013) Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. ACS Chem Neurosci 4:16-21. CrossRef Medline
26. Duan H, Wang J (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 335:743-753. CrossRef Medline
27. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM (2003) Serotonin syndrome and other serotonergic disorders. Pain Med 4:63-74. CrossRef Medline
28. Engel K, Wang J (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68: 1397-1407. CrossRef Medline
29. Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279: 50042-50049. CrossRef Medline
30. Ferrari F, Cassinadri M, Tartoni PL, Tampieri A (1991) Effects of B-HT 920 in the tail-suspension test. Pharmacol Res 24:75-81. CrossRef Medline
31. Fox MA, Jensen CL, Gallagher PS, Murphy DL (2007) Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 53:643-656. CrossRef Medline
32. Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ, Murphy DL (2008) Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT) deficient mice. Psychopharmacology 201:203-218. CrossRef Medline
33. Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Sydney: Academic.
34. Fujishiro J, Imanishi T, Onozawa K, Tsushima M (2002) Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol 454:183-188. CrossRef Medline
35. Fuxe K, Hokfelt T, Ungerstedt U (1967) Studies on uptake mechanisms in central monoamine neurones. Acta Pharmacol Toxicol 25:[Suppl 4]:8. Medline
36. Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758-8766. CrossRef Medline
37. Gasser PJ, Orchinik M, Raju I, Lowry CA (2009) Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 512:529-555. CrossRef Medline
38. Gerhardt GA (1995) Neuromethods: voltammetric methods in brain systems. In: Rapid chronocoulometric measurements of norepinephrine overflow and clearance in CNS tissues, Vol 27 (Boulton AA., Baker GB, Adams RN, eds), pp 117-151. Totowa, NJ: Humana.
39. Grundemann D, Köster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schömig E (1998) Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273: 30915-30920. CrossRef Medline
40. Hagan CE, Schenk JO, Neumaier JF (2011) The contribution of low-affinity transport mechanisms to serotonin clearance in synaptosomes. Synapse 65:1015-1023. CrossRef Medline
41. Hensler JG, Truett KA (1998) Effect of chronic serotonin-2 receptor agonist or antagonist administration on serotonin-1A receptor sensitivity. Neuropsychopharmacology 19:354-364. CrossRef Medline
42. Kalueff AV, Fox MA, Gallagher PS, Murphy DL (2007) Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. Genes Brain Behav 6:389-400. CrossRef Medline
43. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:e45. CrossRef Medline
44. Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, Takagi K, Takagi K, Hasegawa T (2005) Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett 382:195-200. CrossRef Medline
45. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251. CrossRef Medline
46. Kostowski W (1985) Possible relationship of the locus coeruleushippocampal noradrenergic neurons to depression and mode of action of antidepressant drugs. Pol J Pharmacol Pharm 37:727-743. Medline
47. Lamhonwah AM, Hawkins CE, Tam C, Wong J, Mai L, Tein I (2008) Expression patterns of the organic cation/carnitine transporter family in adult murine brain. Brain Dev 30:31-42. CrossRef Medline
48. Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17:208-221. CrossRef Medline
49. Lichtensteiger W, Mutzner U, Langemann H (1967) Uptake of 5-hydroxytryptamine and 5-hydroxytryptophan by neurons of the central nervous system normally containing catecholamines. J Neurochem 14:489-497. CrossRef Medline
50. Middlemiss DN, Fozard JR (1983) 8-hydroxy-2-(di-n-propylamino) tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151-153. CrossRef Medline
51. Montañez S, Owens WA, Gould GG, Murphy DL, Daws LC (2003) Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J Neurochem 86:210-219. Medline
52. 3H]serotonin uptake in rat hippocampal and striatal synaptosomes. Neuropharmacology 53:982-989. CrossRef Medline
53. Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354. CrossRef Medline
54. Perez XA, Andrews AM (2005) Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice. Anal Chem 77:818-826. CrossRef Medline
55. Rea K, Folgering J, Westerink BH, Cremers TI (2010) Alpha1adrenoceptors modulate citalopram-induced serotonin release. Neuropharmacology 58:962-971. CrossRef Medline
56. Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58:303-313. CrossRef Medline
57. Russ H, Friedgen B, Königs B, Schumacher C, Graefe KH, Schömig E (1996) Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. Naunyn Schmiedebergs Arch Pharmacol 354:268-274. Medline
58. Schildkraut JJ, Mooney JJ (2004) Toward a rapidly acting antidepressant: the normetanephrine and extraneuronal monoamine transporter (uptake 2) hypothesis. Am J Psychiatry 161:909-911. CrossRef Medline
59. Schömig E, Babin-Ebell J, Russ H (1993) 1,1-Diethyl-2,2-cyanine (decynium22) potently inhibits the renal transport of organic cations. Naunyn Schmiedebergs Arch Pharmacol 347:379-383. CrossRef Medline
60. Schömig E, Lazar A, Grundemann D (2006) Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency. Handb Exp Pharmacol 175:151-180. CrossRef Medline
61. Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 175:404-418. Medline
62. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705-713. Medline
63. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370. CrossRef Medline
64. Stone EA, Quartermain D (1999) Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol Psychiatry 46:1287-1300. CrossRef Medline
65. Sulzer D, Edwards RH (2005) Antidepressants and the monoamine masquerade. Neuron 46:1-2. CrossRef Medline
66. Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144:616-622. CrossRef Medline
67. Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471-1482. Medline
68. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, Avison MJ, Galli A (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 5:e274. CrossRef Medline
69. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273: 32776-32786. CrossRef Medline
70. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2) an organic cation/carnitine transporter. J Pharmacol Exp Ther 290: 1482-1492. Medline
71. Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF, Grundemann D, Schömig E, Lesch KP, Gerlach M, Reif A (2009) Decreased anxiety in mice lacking organic cation transporter 3. J Neural Transm 116:689-697. CrossRef Medline
72. Zahniser NR, Larson GA, Gerhardt GA (1999) In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J Pharmacol Exp Ther 289:266-277. Medline
73. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP (2001) Impaired activity of the extraneuronal monoamine transporter systems known as uptake-2 in Ort3/Slc22a3-deficient mice. Mol Cell Biol 21: 4188-4196. CrossRef Medline